Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.

Autor:	Hamamoto, Shuzo1 (AUTHOR) hamamo10@med.nagoya-cu.ac.jp, Tasaki, Yoshihiko2 (AUTHOR) phtasaki@med.nagoya-cu.ac.jp, Morikawa, Toshiharu1 (AUTHOR) naiki@med.nagoya-cu.ac.jp, Naiki, Taku1 (AUTHOR) uroetani@med.nagoya-cu.ac.jp, Etani, Toshiki1 (AUTHOR) ktaguchi@med.nagoya-cu.ac.jp, Taguchi, Kazumi1 (AUTHOR) s001013i@yahoo.co.jp, Iwatsuki, Shoichiro1 (AUTHOR) unno@med.nagoya-cu.ac.jp, Unno, Rei1 (AUTHOR) tkd7888@med.nagoya-cu.ac.jp, Takeda, Tomoki1 (AUTHOR) tkshng73@med.nagoya-cu.ac.jp, Nagai, Takashi1 (AUTHOR) kawase@med.nagoya-cu.ac.jp, Kawase, Kengo1 (AUTHOR) a-okada@med.nagoya-cu.ac.jp, Mimura, Yoshihisa2 (AUTHOR) phmimura@med.nagoya-cu.ac.jp, Sugiyama, Yosuke2 (AUTHOR) phsugi@med.nagoya-cu.ac.jp, Okada, Atsushi1 (AUTHOR) yasui@med.nagoya-cu.ac.jp, Furukawa-Hibi, Yoko2 (AUTHOR) yokoh@med.nagoya-cu.ac.jp, Yasui, Takahiro1 (AUTHOR)
Zdroj:	Journal of Clinical Medicine. Jun2024, Vol. 13 Issue 12, p3365. 13p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.